US20130096075A1 - Composition for prevention, amelioration or treatment of metabolic syndrome - Google Patents
Composition for prevention, amelioration or treatment of metabolic syndrome Download PDFInfo
- Publication number
- US20130096075A1 US20130096075A1 US13/261,527 US201113261527A US2013096075A1 US 20130096075 A1 US20130096075 A1 US 20130096075A1 US 201113261527 A US201113261527 A US 201113261527A US 2013096075 A1 US2013096075 A1 US 2013096075A1
- Authority
- US
- United States
- Prior art keywords
- composition
- caffeine
- hesperidin
- mass
- feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 21
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 21
- 230000002265 prevention Effects 0.000 title claims abstract description 21
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 30
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 29
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 26
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 25
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 claims abstract description 24
- 229920001991 Proanthocyanidin Polymers 0.000 claims abstract description 24
- 208000008589 Obesity Diseases 0.000 claims abstract description 21
- 235000020824 obesity Nutrition 0.000 claims abstract description 21
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 20
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 20
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 20
- 229940025878 hesperidin Drugs 0.000 claims abstract description 20
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 20
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 18
- 210000001596 intra-abdominal fat Anatomy 0.000 claims abstract description 16
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 210000004003 subcutaneous fat Anatomy 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000037356 lipid metabolism Effects 0.000 claims abstract description 11
- 229960001587 hesperetin Drugs 0.000 claims abstract description 10
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000010209 hesperetin Nutrition 0.000 claims abstract description 10
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims abstract description 10
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims abstract description 9
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 claims abstract description 9
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 116
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 58
- 229960001948 caffeine Drugs 0.000 claims description 58
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 58
- 230000037396 body weight Effects 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 28
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 claims description 6
- 229960004559 theobromine Drugs 0.000 claims description 4
- 229960000278 theophylline Drugs 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 208000035475 disorder Diseases 0.000 abstract description 4
- 208000004930 Fatty Liver Diseases 0.000 abstract description 3
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 3
- 208000010706 fatty liver disease Diseases 0.000 abstract description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 47
- 229940108690 glucosyl hesperidin Drugs 0.000 description 35
- 239000003925 fat Substances 0.000 description 18
- 239000000306 component Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 210000000577 adipose tissue Anatomy 0.000 description 9
- 235000021050 feed intake Nutrition 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000013616 tea Nutrition 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- -1 hesperetin glycoside Chemical class 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 235000019577 caloric intake Nutrition 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000009278 visceral effect Effects 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000725101 Clea Species 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000008620 Fagopyrum esculentum Species 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 2
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000021016 apples Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 229930182497 flavan-3-ol Natural products 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QUNWUDVFRNGTCO-UHFFFAOYSA-N 1,7-dimethylxanthine Chemical compound N1C(=O)N(C)C(=O)C2=C1N=CN2C QUNWUDVFRNGTCO-UHFFFAOYSA-N 0.000 description 1
- KYHQZNGJUGFTGR-LURJTMIESA-N 7-[(2s)-2-hydroxypropyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C[C@@H](O)C KYHQZNGJUGFTGR-LURJTMIESA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000008375 Decussocarpus nagi Nutrition 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 244000132436 Myrica rubra Species 0.000 description 1
- 235000014631 Myrica rubra Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 229920000124 Prodelphinidin Polymers 0.000 description 1
- 229930182448 Prodelphinidin Natural products 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002783 Propelargonidin Polymers 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 239000003712 decolorant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229960002819 diprophylline Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000015143 herbs and spices Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012961 medicinal therapy Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940100256 oxtriphylline Drugs 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 229960004767 proxyphylline Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A composition comprising (a) and (b), and a food or drink or a medicine comprising the composition, wherein
- (a) is at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and
- (b) is at least a kind of xanthine derivatives,
the mass ratio of (a):(b) in the composition being 1:(0.001 to 5), are useful for the prevention, amelioration, or treatment of metabolic syndrome, disorders of lipid metabolism (for example, fatty liver, hyperlipidemia), obesity (for example, visceral fat accumulation, subcutaneous fat accumulation), or the like.
Description
- The present invention relates to a composition for the prevention, amelioration, or treatment of metabolic syndrome. More specifically, the present invention relates to a composition comprising a polyphenol and a xanthine derivative, for the prevention, amelioration, or treatment of metabolic syndrome.
- In recent years, with steadily increasing obesity, the World Health Organization (WHO) is warning countries around the world of an increased risk of lifestyle-related diseases, which are associated with obesity and include diabetes, hyperlipidemia, hypertension, arteriosclerosis, and fatty liver. Metabolic syndrome is a condition with, in addition to visceral fat accumulation, a combination of risk factors for arteriosclerosis, such as disorders of carbohydrate metabolism (abnormal glucose tolerance, diabetes), disorders of lipid metabolism (hypertriglyceridemia, hypercholesterolemia, and low levels of HDL cholesterol), and hypertension. Even if each of abnormalities (for example, in blood sugar or blood pressure) is mild and at the level of “Care Required” as a result of medical examination or the like, overlapping of such abnormalities tends to cause cardiovascular diseases. It is said that a human having 2 risk factors selected from obesity, hypertension, hyperglycemia, hypertriglyceridemia, and hypercholesterolemia is at the risk of
cardiovascular diseases 10 times higher, and a human having 3 to 4 of such risk factors is at the risk 31 times higher than that of a human not having any of such risk factors. - The co-occurrence of obesity, diabetes, hypertension, and hyperlipidemia increases the risk of developing myocardial infarction or cerebral infarction, and therefore is called “Deadly Quartet”. Accumulation of visceral fat is considered to be the underlying cause eventually resulting in cardiovascular diseases, such as myocardial infarction and cerebral infarction. Therefore, for the prevention or amelioration of metabolic syndrome and also cardiovascular diseases, decreasing the accumulated visceral fat is important. Since obesity is caused by an imbalance between energy intake and expenditure, it is important, for the purpose of inhibiting obesity, to not only decrease energy intake but also increase energy consumption in basal metabolism or activity metabolism. For decreasing energy intake, low-energy replacements for fat and sugar are provided, but the taste or processability thereof in terms of food is not necessarily satisfactory.
- Various measures have been proposed for the prevention of obesity. In recent years, in different kinds of food we regularly take, components having an effect of improving lipid metabolism, or preventing or ameliorating obesity have been found, and are expected to be useful for the prevention of obesity. The inventors focused attention on, among food components having such an effect, hesperidin, a low-molecular proanthocyanidin, and caffeine, which are known to have different working mechanisms with each other. Hesperidin is considered to have an effect of suppressing gene expression of fatty acid synthetase, an effect of increasing gene expression of carnitine palmitoyltransferases I and II, or the like, and thus to promote lipid metabolism (Non Patent Literature 1). Furthermore, it is reported that hesperidin and glucosyl hesperidin have an effect of reducing visceral fat or a waist size (Patent Literature 1). Low-molecular proanthocyanidins are known to have an effect of preventing or improving dysregulated production of adipocytokine and a thermogenic effect by inducing gene expression of uncoupling protein 1 (UCP1) (Non Patent Literature 2). Furthermore, they are known to have an effect of reducing body weight, abdominal circumference, visceral fat, and the like (Non Patent Literature 3). Caffeine is known to have an antagonist effect on adenosine receptors (Non Patent Literature 4), an effect of increasing circulating catecholamine level, and an effect of inhibiting phosphodiesterase activity, which activities facilitate lipid metabolism (Non Patent Literature 5), to inhibit hepatic lipogenesis, and to increase resting metabolic rate and energy consumption, resulting in decrease in body fat and body weight (Non Patent Literature 6). Thus, it is publicly known that each component by itself acts on lipid metabolism. However, there has been no report with regard to combining the components.
-
- Patent Literature 1: JP 2008-156341 A
-
- Proceedings of the 63rd of the Annual Meeting of the Japanese Society of Nutrition and Food Science, 2005, 205
-
- Sakurai et al., Bioscience, Biotechnology, and Biochemistry, 2008, Vol. 72, 463-476
-
- Nishihira et al., J. Functional Foods, Vol. 1, 2009, 341-348
-
- Dodd et al., Sports Med., 1993, Vol. 15, 14-23
-
- Dullo et al., Am. J. Clin. Nutr., 1989, Vol. 49, 44-50
-
- Hollands et al., Am. J. Clin. Nutr., 1981, Vol. 34, 2291-2294
- In order to prevent or decrease obesity, dietary therapy based on restricted calorie intake, exercise therapy, and medicinal therapy by use of an anorexiant, etc. are carried out. However, dietary therapy, which often involves excessively restricted diet, requires complicated calorie calculation and strong will, and therefore is difficult for an individual to manage for a long period of time. Also, exercise therapy, which is associated with mental and physical pain, is very difficult to continue for a long period of time in this busy modern society. It is effective to try to consume as much body fat as possible as energy source during exercise, but people with a tendency to become obese have slow fat metabolism, and it is difficult for them to decrease body fat by exercise. Accordingly, development of a composition that can contribute to the prevention or amelioration of obesity by inhibiting hepatic lipogenesis, facilitating resolution of fat accumulated in fat cells, and effectively burning fat, and so has development of a food or drink or a medicine comprising the composition.
- The present invention was made in the light of the above-mentioned problems, and an objective of the invention is to provide a composition for the prevention, amelioration, or treatment of metabolic syndrome, disorders of lipid metabolism (for example, fatty liver, hyperlipidemia), obesity (for example, visceral fat accumulation, subcutaneous fat accumulation), or the like, and a food or drink or a medicine comprising the composition.
- After intensive investigations into compositions which effectively decrease body fat, the present inventors found that a composition comprising hesperidin or a derivative thereof and caffeine, or a composition comprising a low-molecular proanthocyanidin and caffeine has an anti-obesity effect which is surprisingly stronger than the effect exhibited when each of the components is used alone. The inventors have carried out further investigations and completed the present invention.
- That is, the present invention relates to the following.
- [1] A composition for the prevention, amelioration, or treatment of metabolic syndrome, the composition comprising (a) and (b):
- (a) at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and
- (b) at least a kind of xanthine derivatives, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5).
- [2] The composition according to the above [1], wherein the mass ratio of (a):(b) is 1:(0.01 to 0.5).
- [3] The composition according to the above [1] or [2], wherein the xanthine derivative is caffeine, theophylline, or theobromine.
- [4] A medicine, a food or drink, or a feed comprising the composition according to any of the above [1] to [3].
- [5] A food or drink comprising the composition according to any of the above [1] to [3], the food or drink being labeled as at least one selected from the group consisting of improving lipid metabolism; promoting basal metabolism; reducing body weight; reducing visceral fat or subcutaneous fat; having a slimming effect; preventing or treating obesity, or ameliorating a symptom thereof; and preventing or treating metabolic syndrome, or ameliorating a symptom thereof.
- [6] A method for the prevention, amelioration, or treatment of metabolic syndrome, the method comprising the step of administering an effective amount of a composition comprising (a) and (b):
- (a) at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and
- (b) at least a kind of xanthine derivatives, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5).
- [7] A composition for use for the prevention, amelioration, or treatment of metabolic syndrome, the composition comprising (a) and (b):
- (a) at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and
- (b) at least a kind of xanthine derivatives, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5).
- [8] Use of a composition comprising (a) and (b):
- (a) at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and
- (b) at least a kind of xanthine derivatives, for the production of a medicine for the prevention, amelioration, or treatment of metabolic syndrome, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5).
- The composition of the present invention has an effect of inhibiting body weight increase, visceral fat accumulation, subcutaneous fat accumulation, and increase in plasma triglyceride level, and therefore is useful as a medicine, a food or drink, or a feed for weight loss; prevention or amelioration of obesity; and also prevention, amelioration, or treatment of metabolic syndrome, such as diabetes, hypertriglyceridemia, hypercholesterolemia, and arteriosclerosis, which are considered to result from visceral fat accumulation.
-
FIG. 1 is a graph showing the changes in body weight before and after the test period in Test Example 1. -
FIG. 2 is a graph showing the feed intake during the first 10 days of the test period in Test Example 1. -
FIG. 3 is a graph showing the weight of mesenteric fat tissue per 100 g of body weight in Test Example 1. -
FIG. 4 is a graph showing the changes in body weight before and after the test period in Test Example 2. -
FIG. 5 is a graph showing the feed intake during the first 10 days of the test period in Test Example 2. -
FIG. 6 is a graph showing the weight of subcutaneous fat tissue per 100 g of body weight in Test Example 2. -
FIG. 7 is a graph showing the weight of mesenteric fat tissue per 100 g of body weight in Test Example 2. -
FIG. 8 is a graph showing the changes in body weight before and after the test period in Test Example 3. -
FIG. 9 is a graph showing the feed intake during the first 10 days of the test period in Test Example 3. -
FIG. 10 is a graph showing the total weight of subcutaneous, epididymal, and mesenteric fat tissues per 100 g of body weight in Test Example 3. -
FIG. 11 is a graph showing the changes in plasma triglyceride level before and after the test period. - The present invention provides a composition for the prevention, amelioration, or treatment of metabolic syndrome, the composition comprising (a) and (b), wherein
- (a) is at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and
- (b) is at least a kind of xanthine derivatives, the mass ratio of (b) to 1 part of (a) being 0.001 to 5 parts.
- Hesperidin is a kind of polyphenol found abundantly in the skin of citrus fruits, such as mandarin oranges, and is also called vitamin P. Hesperidin is a hesperetin glycoside, and hesperetin is an aglycon of hesperidin. Examples of hesperidin derivatives include those prepared by addition of a methyl group, an ethyl group, a saccharide, or the like to hesperidin. Examples of hesperidin derivatives having a saccharide include, for example, a glucosyl hesperidin prepared by adding, to hesperidin, one or more kinds of saccharides, such as glucose, fructose, galactose, and xylose, in an equimolar or excess amount with use of a glycosyltransferase. Glucosyl hesperidins can be preferably used in the composition of the present invention because they are excellent in water solubility, processability into food or the like, bioabsorbability, etc. Among glucosyl hesperidins, alpha-glycosyl hesperidin, in which D-glucose residues in an equimolar or excess amount are bound to hesperidin by alpha bonds, is preferred.
- Proanthocyanidin means a group of polyphenol compounds that produce anthocyanidin when treated with an acid, and is a generic term that includes flavan-3-ols (also referred to as catechins); and polymeric procyanidins, prodelphinidins, propelargonidins, and the like which are dimers, trimers, tetramers, and decamers or higher order polymers of flavan-3-ol esterified with gallic acid; and stereoisomers thereof. Proanthocyanidin is known to exist in various plants. Examples of plants containing proanthocyanidin include fruit vegetables, such as astringent persimmons, bananas, apples, pears, grapes, strawberries, avocados, cowberries, hawthorn apples, lotus roots, buckwheat, litchee nuts, and Myrica rubra; herbs and spices; wood; cinnamon; and pine bark.
- In the composition of the present invention, the polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, which is used as the component (a), needs to contain 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, and preferably 20 mass % or more, more preferably 25 mass % or more, further more preferably 30 mass % or more, and particularly preferably 35 mass % or more of such a proanthocyanidin.
- The more proanthocyanidin having a polymerization degree of 1 to 3 is contained, the more preferable the polyphenol is because of its higher bioabsorbability.
- The content of proanthocyanidin having a polymerization degree of 1 to 3 in the polyphenol can be determined by a publicly known measuring method, such as HPLC. As a method for increasing the content of proanthocyanidin having a polymerization degree of 1 to 3 in the polyphenol, for example, a method of discarding polyphenol portions other than proanthocyanidin having a polymerization degree of 1 to 3, or a method of decomposing proanthocyanidin having a polymerization degree of 4 or more into low molecules (see, for example, WO 2006/090830) can preferably be used.
- A composition containing a polyphenol containing 15% or more of proanthocyanidin having a polymerization degree of 1 to 3 is commercially available (for example, Oligonol (trade name), AMINO UP CHEMICAL Co. , Ltd.), and such a product can also be preferably used as the component (a) of the present invention.
- The component (a) may be any one kind, or a combination of two or more kinds selected from a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin.
- Examples of the xanthine derivatives include xanthin, aminophylline, theophylline, cholinetheophylline, caffeine, theobromine, 1,7-dimethylxanthin, oxtriphylline, diprophylline, and proxyphylline. Inter alia, caffeine, theophylline, and theobromine are preferred.
- The component (b) may be any one kind, or a combination of two or more kinds in combination of the xanthine derivatives exemplified above.
- The blending ratio (mass ratio) of the component (a) and component (b) in the composition of the present invention is not particularly limited as long as the desired effects of the present invention can be achieved, but the mass ratio of (a):(b) is preferably about 1:(0.001 to 5), more preferably about 1:(0.01 to 0.5), and still more preferably about 1:(0.02 to 0.3).
- The composition of the present invention has been confirmed to have an effect of inhibiting body weight increase, visceral fat accumulation, subcutaneous fat accumulation, and increase in plasma triglyceride level (see Test Examples 1 to 3), and therefore can be preferably used for the prevention, amelioration, or treatment of metabolic syndrome. The components (a) and (b) in the composition of the present invention, which are each already known to be useful when used alone for improving lipid metabolism or the like, are very useful when used in combination with each other, in that they exhibit a much stronger effect than in the cases where they are used alone, and that they produce a prominent effect even at low doses at which they separately cannot work (see Test Examples 1 to 3).
- The composition of the present invention can be used as a medicine, a food or drink, a feed, a food additive, a feed additive, or the like. The composition is particularly preferable for use in a medicine, a food or drink, or a feed.
- A medicine comprising the composition of the present invention may be orally or parenterally administered to a mammal. Examples of oral preparations include a granule, a powder, a tablet (including a sugar-coated tablet), a pill, a capsule, a syrup, an emulsion, and a suspension. Examples of parenteral preparations include injections (for example, a subcutaneous injection, an intravenous injection, an intramuscular injection, and an intraperitoneal injection), an intravenous fluid, external preparations (for example, an intranasal preparation, a transdermal preparation, and an ointment), and suppositories (for example, an intrarectal suppository and an intravaginal suppository). These preparations can be formulated with use of a pharmaceutically acceptable carrier by a method conventionally used in the art. Examples of the pharmaceutically acceptable carrier include an excipient, a binder, a diluent, an additive, a flavor, a buffer, a thickener, a colorant, a stabilizer, an emulsifier, a dispersant, a suspending agent, a preservative, and the like. For example, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low-melting-point wax, cacao butter, or the like can be used as the carrier.
- Oral solid preparations (a tablet, a pill, a capsule, a powder, a granule, or the like) can be formulated by conventional means including mixing an active ingredient with an excipient (lactose, mannitol, glucose, microcrystalline cellulose, starch, or the like), a binder (hydroxypropylcellulose, polyvinyl pyrrolidone, magnesium aluminometasilicate, or the like), a disintegrant (calcium cellulose glycolate, or the like), a lubricant (magnesium stearate, or the like), a stabilizer, a solubilizer (glutamic acid, aspartic acid, or the like), or the like. As needed, such preparations may be coated with a coating agent (saccharose, gelatin, hydroxypropylcellulose, hydroxypropyl methylcellulose phthalate, or the like), and the coating may consists of 2 or more layers.
- Oral liquid preparations (a potus, a suspension, an emulsion, a syrup, an elixir, or the like) are formulated by dissolving, suspending, or emulsifying an active ingredient in a generally used diluent (purified water, ethanol, or the mixture thereof, or the like). The liquid preparation may further comprise a wetting agent, a suspending agent, an emulsifier, a sweetener, a flavor, an essence, a preservative, a buffer, or the like.
- Injections include a solution, a suspension, an emulsion, and a solid injection to be dissolved or suspended in a solvent before use. Injections are formulated by dissolving, suspending, or emulsifying an active ingredient in a solvent. As the solvent, for example, distilled water for injection; physiological saline; a vegetable oil; alcohols, such as propylene glycol, polyethylene glycol, and ethanol; and a combination thereof may be used. The injection may further comprise a stabilizer, a solubilizer (glutamic acid, aspartic acid, Polysorbate 80 (registered trademark), or the like), a suspending agent, an emulsifier, a soothing agent, a buffer, a preservative, or the like. These injections are sterilized in the final step or produced by aseptic manipulation. The injection may be produced in a form of a sterile solid preparation, for example a lyophilized product, which can be dissolved in sterilized or sterile distilled water for injection or in another sterilized or sterile solvent just before use.
- To a food or drink comprising the composition of the present invention, food additives generally used in a food or drink may be added, and the examples thereof include a sweetener, a colorant, a preservative, a thickener, an antioxidant, a color improver, a decolorant, an antifungal agent, a gum base, a bittering agent, an enzyme, a brightener, an acidulant, a seasoning, an emulsifier, a fortifier, a processing aid, a flavor, a spice extract, etc. The food or drink includes a health food, a functional food, a food for specified health use, and a food for the sick.
- The food or drink suitable for the present invention is not particularly limited. Specific examples thereof include so-called dietary supplements, such as a tablet, a granule, a powder, and a health drink. Other examples include drinks, such as tea drink, refreshing drink, soda, nutritional drink, fruit juice, and lactic drink; noodles, such as buckwheat noodle, wheat noodle, Chinese noodle, and instant noodle; sweets and bakery products, such as candy, candy, gum, chocolate, snack, biscuit, jelly, jam, cream, baked goods, and bread; fishery or livestock products, such as fish sausage, ham, and sausage; dairy products, such as processed milk and fermented milk; fats, oils, and processed foods thereof, such as salad oil, oil for frying, margarine, mayonnaise, shortening, whipped cream, and dressing; seasonings, such as sauce and dipping sauce; retort pouch foods, such as curry, stew, sauce for rice-bowl cuisine, porridge, and rice soup; and frozen desserts, such as ice cream, sherbet, and shaved ice.
- In light of the effects of the composition of the present invention, a food or drink prepared with use of the composition may be labeled as improving lipid metabolism; promoting basal metabolism; reducing body weight; reducing visceral fat or subcutaneous fat; having a slimming effect; preventing or treating obesity, or ameliorating a symptom thereof; and/or preventing or treating metabolic syndrome, or ameliorating a symptom thereof.
- Examples of the feed comprising the composition of the present invention include a feed for livestock such as a cow, a horse, and a pig; a feed for poultry such as a chicken; and a feed for pet animals, such as a dog and a cat. The production of the feed of the present invention needs addition of the composition of the present invention, but other than that, the feed can be produced by an ordinary feed production method.
- The amount of administration or intake of the medicine or the food or drink of the present invention may be determined depending on the age and body weight of the patient or ingester, symptoms, the administration time, the dosage form, the administration method, the combination of medicines, or the like. For example, preferred is that administration or intake is performed so that 0.05 to 3.0 g, preferably 0.2 to 1.0 g of the component (a) and 0.01 to 0.5 g, preferably 0.05 to 0.3 g of the component (b) are daily given to an adult human. Such a daily amount may be given in a single dose or in several divided doses.
- Hereinafter, the present invention will be illustrated in more detail by Examples and Test Examples, but the present invention is not limited thereto.
- Powder ingredients, namely, glucosyl hesperidin (0.2 g), caffeine (0.02 g), vitamin C (0.28 g), synthetic aluminum silicate (10 g), potassium hydrogenphosphate (5 g), and lactose (84.5 g) were mixed uniformly to give a powder.
- Powder ingredients, namely, glucosyl hesperidin (0.2 g), caffeine (0.02 g), vitamin C (0.28 g), crystalline cellulose (40.0 g), lactose (35.0 g), starch (19.5 g), and polyvinyl alcohol (5.0 g), and water (30.0 g) were kneaded uniformly, ground and granulated, and then dried to give a granule.
- With 99 g of the granule obtained in Example 2, 1 g of calcium stearate was mixed, and the mixture was compressed with use of a tableting machine to give tablets 6.0 mm in diameter.
- Extraction from 1 g of a blend of 7 kinds of dried tea leaves, namely, green tea leaves, Job's tears, barley, brown rice, oolong tea leaves, Houttuynia cordata leaves, and Eucommia ulmoides leaves was performed with 100 mL of water. With the extract, glucosyl hesperidin (100 mg), caffeine (10 mg including 2 mg of ingredient-derived caffeine) and vitamin C (15 mg) were blended to give a blended tea.
- Brown rice tea extract (1800 mg), lactose (500 mg), citric acid (500 mg), glucosyl hesperidin (550 mg), and caffeine (55 mg including 20 mg of ingredient-derived caffeine) were blended to give a powdered tea.
- Glucosyl hesperidin (200 mg), caffeine (20 mg), citric acid (100 mg), vitamin C (15 mg), starch syrup (65 g), sucrose (10 g), maleic acid (300 mg), succinic acid (200 mg), malic acid (150 mg), a flavor (0.3 g), and a small amount of water were mixed, and then heated and cooled in a conventional method to produce candies.
- When diet-induced obese mice were placed in a situation where caloric intake is controlled and they need to decompose and use body fat, decomposition and use of body fat is promoted, ameliorating obesity. In such a situation, the effect of the composition of the present invention comprising glucosyl hesperidin and caffeine was investigated. As the glucosyl hesperidin and caffeine, “Hayashibara Hesperidin S (trade name)” (distributor: Hayashibara Co., Ltd.) and “Chanomoto (trade name)” (purity of caffeine: 98.5, made by Shiratori Pharmaceutical Co., Ltd.) were used, respectively.
- Five-week-old male KK mice were fed with water and a powder feed for breeding (CE-2 (trade name), made by CLEA Japan, Inc.) for one week, and then fed with the high-calorie feed (4.70 kcal/g) in Table 1 shown below for 3 weeks for induction of obesity. The mice were divided into 4 groups (a control group, a caffeine administration group, a glucosyl hesperidin administration group, and a present invention administration group (caffeine+glucosyl hesperidin), 5 to 8 mice per group) and fed with the low-calorie feed (3.16 kcal/g) in Table 1 shown below or the low-calorie feed supplemented with the corresponding test sample for 2 weeks, in expectation of using body fat. The feeds given to the test groups are as follows.
- (1) Control group; low-calorie feed
- (2) Caffeine administration group; low-calorie feed+0.025 mass % of caffeine
- (3) Glucosyl hesperidin administration group; low-calorie feed+0.25 mass % of glucosyl hesperidin
- (4) Present invention (mixture of glucosyl hesperidin and caffeine (10:1)) administration group; low-calorie feed+(0.25 mass % of glucosyl hesperidin+0.025 mass % of caffeine)
-
TABLE 1 Compositions of high-calorie feed and low-calorie feed (Unit: mass %) Composition High-calorie feed Low-calorie feed Cornstarch 53.25 53.25 Casein 18.00 18.00 Corn oil 20.00 2.50 Cellulose 2.50 20.00 AIN93G Mineral Mix1) 5.00 5.00 AIN93 Vitamin Mix1) 1.00 1.00 Choline bitartrate 0.25 0.25 Calorie (kcal/g) 4.73 3.16 1)Made by Oriental Yeast Co., Ltd. - During the test period (2 weeks from the start of low-calorie feeding), body weight and feed intake were periodically measured. After the end of the test, the mice were euthanized, and mesenteric (visceral) fat tissue was removed and weighed.
- The changes in body weight before and after the test period is shown in
FIG. 1 , the feed intake during the first 10 days of the test period is shown inFIG. 2 , and the weight of mesenteric fat tissue per 100 g of body weight is shown inFIG. 3 . The results are shown as Mean±SD of each group. The ** and * in the figures indicate a significant difference with a risk less than 1% and a risk less than 5% from the control, respectively. - These results show the following. Regarding the weight of mesenteric (visceral) fat tissue, while the caffeine administration group and the glucosyl hesperidin administration group did not show any significant difference as compared with the control group, the present invention administration group showed significantly lower values, i.e., a clear synergistic effect. Also, regarding the changes in body weight, as compared with the control group, the caffeine administration group showed significantly lower values, but the glucosyl hesperidin administration group showed equivalent values. Meanwhile, the present invention administration group showed significantly lower values, which were even lower than those of the caffeine administration group, i.e., a clear synergistic effect. These results showed that the composition of the present invention comprising glucosyl hesperidin and caffeine, due to the clear synergistic effect of reducing body weight and visceral fat, is useful for the prevention or amelioration of metabolic syndrome.
- Under the same conditions as in Test Example 1, the effect of the composition of the present invention comprising glucosyl hesperidin and caffeine was investigated. The glucosyl hesperidin and caffeine used here were the same as in Test Example 1.
- Five-week-old male KK mice were fed with water and a powder feed for breeding (CE-2 (trade name), made by CLEA Japan, Inc.) for one week, and then fed with the high-calorie feed (4.70 kcal/g) in Table 1 for 3 weeks for induction of obesity. The mice were divided into 6 groups (a control group, a caffeine administration group, a glucosyl hesperidin administration group, and mixture of caffeine and glucosyl hesperidin (present invention) administration groups, 6 to 7 mice per group) and fed with the low-calorie feed (3.16 kcal/g) in Table 1 or the low-calorie feed supplemented with the corresponding test sample for 2 weeks, in expectation of using body fat. The feeds given to the test groups are as follows.
- (1) Control group; low-calorie feed
- (2) Caffeine administration group; low-calorie feed+0.0125 mass % of caffeine
- (3) Glucosyl hesperidin administration group; low-calorie feed+0.25 mass % of glucosyl hesperidin
- (4) Mixture of glucosyl hesperidin and caffeine (10:1) administration group; low-calorie feed+(0.25 mass % of glucosyl hesperidin+0.025 mass % of caffeine)
- (5) Mixture of glucosyl hesperidin and caffeine (20:1) administration group; low-calorie feed+(0.25 mass % of glucosyl hesperidin+0.0125 mass % of caffeine)
- (6) Mixture of glucosyl hesperidin and caffeine (40:1) administration group; low-calorie feed+(0.25 mass % of glucosyl hesperidin+0.00625 mass % of caffeine)
- During the test period (2 weeks from the start of low-calorie feeding), body weight and feed intake were periodically measured. After the end of the test, the mice were euthanized, and subcutaneous fat tissue and mesenteric (visceral) fat tissue were removed and separately weighed.
- The changes in body weight before and after the test period is shown in
FIG. 4 , the feed intake during the first 10 days of the test period is shown inFIG. 5 , the weight of subcutaneous fat tissue per 100 g of body weight is shown inFIG. 6 , and the weight of mesenteric fat tissue per 100 g of body weight is shown inFIG. 7 . The results are shown as Mean±SD of each group. The $, **, and * in the figures indicate a significant difference with a risk less than 10%, a risk less than 1%, and a risk less than 5% from the control, respectively. - These results show the following. Regarding the weight of mesenteric (visceral) fat tissue and the weight of subcutaneous fat tissue, while the caffeine administration group and the glucosyl hesperidin administration group did not show any significant difference as compared with the control group, the present invention (mixture of glucosyl hesperidin and caffeine) administration groups showed significantly lower values, i.e., a clear synergistic effect. Also, regarding the changes in body weight, the caffeine administration group and the glucosyl hesperidin administration group showed values equivalent to those of the control group. Meanwhile, the present invention (mixture of glucosyl hesperidin and caffeine) administration groups showed lower values, i.e., a clear synergistic effect. These results showed that the composition of the present invention comprising glucosyl hesperidin and caffeine, due to the clear synergistic effect of reducing body weight, visceral fat accumulation, and subcutaneous fat accumulation, is useful for the prevention or amelioration of metabolic syndrome.
- Under the same conditions as in Test Example 1, the effect of the composition of the present invention comprising a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3 and caffeine was investigated. As the polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3 and caffeine, “Oligonol (trade name)” (distributor: AMINO UP CHEMICAL Co., Ltd.) and “Chanomoto (trade name)” (purity of caffeine: 98.5%, made by Shiratori Pharmaceutical Co., Ltd.) were used, respectively.
- Five-week-old male KK mice were fed with water and a powder feed for breeding (CE-2 (trade name), made by CLEA Japan, Inc.)
- for one week, and then fed with the high-calorie feed (4.70 kcal/g) in Table 1 for 3 weeks for induction of obesity. The mice were divided into 4 groups (a control group, a caffeine administration group, an Oligonol administration group, and a present invention administration group (Oligonol+caffeine), 5 to 8 mice per group) and fed with the low-calorie feed (3.16 kcal/g) in Table 1 or the low-calorie feed supplemented with the corresponding test sample for 2 weeks, in expectation of using body fat. The feeds given to the test groups are as follows.
- (1) Control group; low-calorie feed
- (2) Caffeine administration group; low-calorie feed+0.025 mass % of caffeine
- (3) Oligonol administration group; low-calorie feed+0.1 mass of Oligonol
- (4) Present invention (mixture of Oligonol and caffeine (4:1)) administration group; low-calorie feed+(0.1 mass % of Oligonol+0.025 mass % of caffeine)
- During the test period (2 weeks from the start of low-calorie feeding), body weight and feed intake were periodically measured. After the end of the test, the mice were euthanized, and subcutaneous fat tissue, epididymal fat tissue, and mesenteric (visceral) fat tissue were removed and separately weighed. Also, at the start of the test period (the start of low-calorie feeding) and the end of the test period, plasma triglyceride level was measured.
- The changes in body weight before and after the test period is shown in
FIG. 8 , the feed intake during the first 10 days of the test period is shown inFIG. 9 , the total weight of subcutaneous, epididymal, and mesenteric fat tissues per 100 g of body weight is shown inFIG. 10 , and the changes in plasma triglyceride level before and after the test period is shown inFIG. 11 . The results are shown as Mean±SD of each group. The ** and * in the figures indicate a significant difference with a risk less than 1% and a risk less than 5% from the control, respectively. - These results show the following. Regarding the total weight of fat tissues, while the caffeine administration group and the Oligonol administration group did not show any significant difference as compared with the control group, the present invention administration group showed significantly lower values, i.e., a clear synergistic effect. Regarding the changes in body weight, while the caffeine administration group and the Oligonol administration group showed lower values as compared with the control group, the present invention administration group showed even lower values, i.e., a clear synergistic effect. Further, regarding the values of plasma triglyceride level measured on the 14th day, while the caffeine administration group and the Oligonol administration group did not show any significant difference as compared with the control group, the present invention administration group showed significantly lower values, i.e., a clear synergistic effect. These results showed that the composition of the present invention comprising Oligonol and caffeine, due to the clear synergistic effect of reducing body weight, visceral fat accumulation, and subcutaneous fat accumulation, and of inhibiting increase in plasma triglyceride level, is useful for the prevention, amelioration, or treatment of metabolic syndrome.
Claims (5)
1. A composition for the prevention, amelioration, or treatment of metabolic syndrome, the composition comprising (a) and (b):
(a) at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and
(b) at least a kind of xanthine derivatives, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5).
2. The composition according to claim 1 , wherein the mass ratio of (a):(b) is 1:(0.01 to 0.5).
3. The composition according to claim 1 , wherein the xanthine derivative is caffeine, theophylline, or theobromine.
4. A medicine, a food or drink, or a feed comprising the composition according to claim 1 .
5. A food or drink comprising the composition according to claim 1 , the food or drink being labeled as at least one selected from the group consisting of improving lipid metabolism; promoting basal metabolism; reducing body weight; reducing visceral fat or subcutaneous fat; having a slimming effect; preventing or treating obesity, or ameliorating a symptom thereof; and preventing or treating metabolic syndrome, or ameliorating a symptom thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/733,592 US9993493B2 (en) | 2010-05-24 | 2015-06-08 | Composition for prevention, amelioration or treatment of metabolic syndrome |
US15/975,729 US20180264020A1 (en) | 2010-05-24 | 2018-05-09 | Composition for prevention, amelioration or treatment of metabolic syndrome |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010118051A JP5564330B2 (en) | 2010-05-24 | 2010-05-24 | Composition for prevention, amelioration or treatment of metabolic syndrome |
JP2010-118051 | 2010-05-24 | ||
PCT/JP2011/050495 WO2011148657A1 (en) | 2010-05-24 | 2011-01-14 | Composition for prevention, amelioration or treatment of metabolic syndrome |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/050495 A-371-Of-International WO2011148657A1 (en) | 2010-05-24 | 2011-01-14 | Composition for prevention, amelioration or treatment of metabolic syndrome |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/733,592 Continuation US9993493B2 (en) | 2010-05-24 | 2015-06-08 | Composition for prevention, amelioration or treatment of metabolic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130096075A1 true US20130096075A1 (en) | 2013-04-18 |
Family
ID=45003652
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/261,527 Abandoned US20130096075A1 (en) | 2010-05-24 | 2011-01-14 | Composition for prevention, amelioration or treatment of metabolic syndrome |
US14/733,592 Active 2031-08-20 US9993493B2 (en) | 2010-05-24 | 2015-06-08 | Composition for prevention, amelioration or treatment of metabolic syndrome |
US15/975,729 Abandoned US20180264020A1 (en) | 2010-05-24 | 2018-05-09 | Composition for prevention, amelioration or treatment of metabolic syndrome |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/733,592 Active 2031-08-20 US9993493B2 (en) | 2010-05-24 | 2015-06-08 | Composition for prevention, amelioration or treatment of metabolic syndrome |
US15/975,729 Abandoned US20180264020A1 (en) | 2010-05-24 | 2018-05-09 | Composition for prevention, amelioration or treatment of metabolic syndrome |
Country Status (4)
Country | Link |
---|---|
US (3) | US20130096075A1 (en) |
JP (1) | JP5564330B2 (en) |
KR (1) | KR101490730B1 (en) |
WO (1) | WO2011148657A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6034107B2 (en) * | 2012-09-25 | 2016-11-30 | 日本メナード化粧品株式会社 | Differentiation promoter from stem cells to brown adipocytes |
JP6453534B2 (en) * | 2012-09-28 | 2019-01-16 | 小林製薬株式会社 | Lipid metabolism promoter |
TWI705132B (en) | 2015-10-08 | 2020-09-21 | 日商三菱瓦斯化學股份有限公司 | Liquid composition for cleaning semiconductor element, cleaning method of semiconductor element, and manufacturing method of semiconductor element |
WO2018074929A2 (en) | 2016-10-20 | 2018-04-26 | Rijksuniversiteit Groningen | Drugs mimicking calorie restriction and tools and methods for identifying the same |
JP6667773B1 (en) * | 2018-12-20 | 2020-03-18 | 公益財団法人 佐賀県地域産業支援センター | Composition for suppressing inflammatory cytokine production |
JP7350304B2 (en) * | 2019-10-18 | 2023-09-26 | 国立大学法人徳島大学 | Allergic rhinitis symptom suppressant |
JP7224008B1 (en) | 2022-08-30 | 2023-02-17 | 株式会社東洋新薬 | oral composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005047839A (en) * | 2003-07-31 | 2005-02-24 | Toyo Shinyaku:Kk | Proanthocyanidin-containing composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4676040B2 (en) * | 1997-07-31 | 2011-04-27 | 株式会社林原生物化学研究所 | Composition |
JP4179765B2 (en) * | 2001-07-19 | 2008-11-12 | 花王株式会社 | Lipid metabolism improver |
JP2004035417A (en) * | 2002-06-28 | 2004-02-05 | Kao Corp | Elevating drug for blood total ketone substance level |
WO2006067866A1 (en) * | 2004-12-24 | 2006-06-29 | Toyo Shinyaku Co., Ltd. | Proanthocyanidin-containing composition |
JP2008156341A (en) * | 2006-12-01 | 2008-07-10 | Daiichi Sankyo Healthcare Co Ltd | Agent for reducing waist size |
US20100166851A1 (en) * | 2007-05-04 | 2010-07-01 | Nutraceutic Et Business Consulting | Composition having lipolytic activity, production method thereof and use of the composition |
EP2163252A4 (en) * | 2007-05-17 | 2012-01-11 | Kaneka Corp | Composition containing licorice-derived polyphenol |
JP5121308B2 (en) * | 2007-05-28 | 2013-01-16 | ハウスウェルネスフーズ株式会社 | Composition for preventing, improving or treating metabolic syndrome |
JP5517421B2 (en) * | 2007-08-03 | 2014-06-11 | 花王株式会社 | Container drink |
US20100273727A1 (en) * | 2007-12-28 | 2010-10-28 | Unitika Ltd. | Oral administration composition |
-
2010
- 2010-05-24 JP JP2010118051A patent/JP5564330B2/en active Active
-
2011
- 2011-01-14 US US13/261,527 patent/US20130096075A1/en not_active Abandoned
- 2011-01-14 WO PCT/JP2011/050495 patent/WO2011148657A1/en active Application Filing
- 2011-01-14 KR KR1020127033286A patent/KR101490730B1/en active IP Right Grant
-
2015
- 2015-06-08 US US14/733,592 patent/US9993493B2/en active Active
-
2018
- 2018-05-09 US US15/975,729 patent/US20180264020A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005047839A (en) * | 2003-07-31 | 2005-02-24 | Toyo Shinyaku:Kk | Proanthocyanidin-containing composition |
Non-Patent Citations (3)
Title |
---|
Definition of "prevention" from the Institute for International Medical Education [online], [Retrieved on 24 March 2011]. Retrieved from the internet . Published February 2002, p. 1, 2, 26, 27 and 39. * |
Machine translation of JP2005-47839 (2005) [online] [Retrieved 4 February 2015] Retrieved from the internet * |
Maureen Rouhi, A. (2004) Metabolic Syndrome. Chemical & Engineering News, vol. 82, no. 47, p. 83-99. * |
Also Published As
Publication number | Publication date |
---|---|
KR20130029415A (en) | 2013-03-22 |
WO2011148657A1 (en) | 2011-12-01 |
JP2011246355A (en) | 2011-12-08 |
US9993493B2 (en) | 2018-06-12 |
JP5564330B2 (en) | 2014-07-30 |
US20150265645A1 (en) | 2015-09-24 |
KR101490730B1 (en) | 2015-02-06 |
US20180264020A1 (en) | 2018-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9993493B2 (en) | Composition for prevention, amelioration or treatment of metabolic syndrome | |
JP5121308B2 (en) | Composition for preventing, improving or treating metabolic syndrome | |
US9492424B2 (en) | Muscle atrophy inhibitor | |
US9669063B2 (en) | Composition for prevention, amelioration or treatment of metabolic syndrome | |
JPWO2004083179A1 (en) | Diabetes treatment | |
JP4022350B2 (en) | Composition having an inhibitory effect on cholesterol elevation and an inhibitory effect on HDL-cholesterol lowering | |
AU2013367872B2 (en) | Igf-1 production-promoting agent | |
US20210177874A1 (en) | Composition for preventing or alleviating nonalcoholic fatty liver disease | |
KR101890853B1 (en) | A composition for prevention or treatment of obesity comprising protamine and chitooligosaccharide | |
JP7156639B2 (en) | New applications of resveratrol derivatives | |
JP5048258B2 (en) | Rebound inhibitor | |
JP2004292325A (en) | Anabolic steroid, and prophylactic or therapeutic agent for muscle attenuation | |
EP2815756B1 (en) | Composition for preventing, ameliorating or treating metabolic syndrome | |
KR101830480B1 (en) | Pharmaceutical composition for preventing or treating hypertriglyceridemia comprising methyl linolenate | |
KR101699123B1 (en) | Composition for decreasing corticosterone | |
JP2023103165A (en) | Atp production promoter, anti-inflammatory agent, and food/drink product | |
KR20050113251A (en) | Lipid metabolism improving agent | |
JP2014024804A (en) | Lipid metabolism-improving agent containing decomposition product of ovalbumin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOUSE WELLNESS FOODS CORPORATION, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OHARA, TATSUYA;MUROYAMA, KOUTAROU;MUROSAKI, SHINJI;AND OTHERS;REEL/FRAME:029532/0282 Effective date: 20121121 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |